Edition:
India

People: Intra-Cellular Therapies Inc (ITCI.OQ)

ITCI.OQ on NASDAQ Stock Exchange Global Select Market

12.67USD
1:10am IST
Change (% chg)

$-0.38 (-2.91%)
Prev Close
$13.05
Open
$13.05
Day's High
$13.18
Day's Low
$12.63
Volume
41,826
Avg. Vol
123,307
52-wk High
$23.49
52-wk Low
$10.24

Davis, Robert 

Mr. Robert E. Davis is Ph.D., is the Senior Vice President and Chief Scientific Officer of Intra-Cellular Therapies, Inc. Mr Davis previously served as President and CEO of 3-D Pharmaceutical Consultants, providing consulting services to the Company from December 2005 to November 2015. From December 2000 until November 2005, Dr. Davis served as the Executive Vice President, Research and Development at ACADIA Pharmaceuticals. From January 1994 until October 2000, Dr. Davis held various positions at MitoKor, a development stage biotechnology company focused on the design and development of drug therapies for mitochondrial diseases, serving at various times as its President, Chief Executive Officer and Chief Scientific Officer. Earlier, Dr. Davis held various positions at Parke-Davis Pharmaceutical Research, Warner-Lambert. Earlier in his career, he participated in the discovery and development of Cognex, the first drug approved for treating Alzheimer’s disease, Neurontin, the first drug approved for treating neuropathic pain, and Nuplazid, a potential new treatment for psychosis associated with Parkinson disease. Dr. Davis received his B.S., M.S and Ph.D in Psychobiology from the University of Illinois.

Basic Compensation

Total Annual Compensation, USD 628,100
Restricted Stock Award, USD 749,986
Long-Term Incentive Plans, USD --
All Other, USD 750,454
Fiscal Year Total, USD 2,128,540

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Lawrence Hineline

2,127,810

Michael Halstead

2,193,200

Mark Neumann

--

Andrew Satlin

2,018,330

Robert Davis

2,128,540

John Bardi

--
As Of  31 Dec 2018